The Oncology InstituteTOIIW 56 Forward PE Ratio is 0.00 as of Jul. 04, 2026. GuruFocus rates TOIIW with a GF Score™ of 56/100. The stock has 6 warning signs investors should review. Among 312 Healthcare Providers & Services companies, The Oncology Institute ranks worse than 320512.5% on this metric.
The Oncology Institute (NAS:TOIIW) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
The Oncology Institute Forward PE Ratio Related Terms
The Oncology Institute Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for The Oncology Institute's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute Forward PE Ratio Chart
The Oncology Institute Annual Data
Trend
Forward PE Ratio
The Oncology Institute Quarterly Data
Forward PE Ratio
TOIIW vs CYH, SRTA, CCRN: Forward PE Ratio Comparison
For the Medical Care Facilities subindustry, The Oncology Institute's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Oncology Institute Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's Forward PE Ratio falls into.
The Oncology Institute Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
The Oncology Institute (TOIIW) has a Forward PE Ratio of 0.00 as of Jul. 04, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on The Oncology Institute and its competitors. According to the industry distribution chart, The Oncology Institute ranks #999999 out of 312 companies in the Healthcare Providers & Services industry.
Is The Oncology Institute's Forward PE Ratio too high?
The Oncology Institute's current Forward PE Ratio is 0.00. Based on the distribution chart, The Oncology Institute ranks #999999 out of 312 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, The Oncology Institute has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's Forward PE Ratio compare to CYH and SRTA?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #999999 out of 312 companies for Forward PE Ratio. This places The Oncology Institute in the lower half of its industry. The industry median Forward PE Ratio is 18.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.33, based on 312 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on The Oncology Institute and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Oncology Institute's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. The Oncology Institute's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current Forward PE Ratio is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for TOIIW
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOIIW has been successfully added to your 